Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Aristada® (aripiprazole lauroxil) – New formulation approval
June 6, 2017 – Alkermes announced the FDA approval of two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension, for the treatment of schizophrenia.
